StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) company profile

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.92−0.19 (-9.00%)

Close on Nov 18, 2026Market cap $61.21MP/E –Yield –

About Longeveron

Pharmaceutical Preparations, SIC 2834

Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for unmet medical conditions. Its primary investigational product candidate is laromestrocel, an allogeneic cell therapy designed to promote tissue repair and reduce inflammation. The firm focuses on advancing treatments across several therapeutic indications, including hypoplastic left heart syndrome, Alzheimer’s disease, aging-related frailty, and pediatric dilated cardiomyopathy. Its customer and user base includes clinical trial participants, patients, and third-party partners seeking contract development and manufacturing services.

The company is headquartered in Miami, Florida, where it operates a manufacturing facility equipped with eight clean rooms, two research and development laboratories, and warehouse space. Its clinical operations and research activities take place in the United States, and it sponsors a patient registry program located in The Bahamas. Additionally, the organization maintains bone marrow supply agreements with multiple external partners to support product production.

Summary of the business section of Longeveron's latest annual report, written by StockData.

Company profile

Company

Legal name
Longeveron Inc.
Founded
2014
Headquarters
Miami, FL
Address
1951 Nw 7th Avenue, Suite 520 33136
Phone
(305) 302-7158
Employees
37, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum LLPMarcum LLP, Hartford, CT

Stock & identifiers

Ticker
LGVN
Exchange
Nasdaq
IPO date
Feb 12, 2021
Shares outstanding
32M, Aug 6, 2026
Public float
$16.49M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-10 reverse, Aug 27, 2026; 1-for-10 reverse, Mar 27, 2024
SEC CIK
1721484
CUSIP
54303L302
ISIN
US54303L3024
FIGI
BBG00YZ6JHT4
Share class FIGI
BBG00YZ6JJN6
EIN
47-2174146

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Joshua HareChief Scientific Officer, Director10,811,369
Nirav S. JhaveriChief Financial Officer29,258
Paul T. LehrGeneral Counsel, Secretary226,295
Stephen H. WillardChief Executive Officer74,916
Nataliya AgafonovaChief Medical Officer89,564
Devin BlassCTO & SVP of CMC68,653
Marie WashburnChief Financial Officer101,030
Lisa LocklearChief Financial Officer480,005
James Nathaniel PowellChief Executive Officer125,593
Mohamed Wa'el Ahmed HashadChief Executive Officer543,547
Roger Joseph HajjarDirector69,000
Leah Rush CannDirector36,000
Deborah AscheimDirector36,000
George A. Paletta Jr.Director70,000
Arjun JJ DesaiDirector36,000
Ursula UngaroDirector77,000
Rock SofferDirector964,385
Khoso BaluchDirector67,391
Richard N. KenderDirector33,000
Neha J. MotwaniDirector33,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
J. Nathaniel Powell
Former Interim Chief Executive Officer
$194.39K$112.23K$10.63K$135.55K$23.03K$475.82K–
Wa’el Hashad
Former Chief Executive Officer
$482.18K$264.60K$65.55K–$468.92K$1.28M-31%
Lisa A. Locklear
Chief Financial Officer and Treasurer
$431.69K$149.94K$37.15K$199.35K$43.96K$862.09K-23%
Paul Lehr
General Counsel and Corporate Secretary
$419.98K$337.44K$37.15K$193.95K$61.01K$1.05M-14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 12, 2021
Offer price
$10.00
Securities offered
2,660,000
Gross proceeds
$26.60M
Exchange
Nasdaq
First trading day
Feb 12, 2021
First-day close
$7.41-25.9%
Lock-up ends (est.)
Aug 11, 2021

“The initial public offering price is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 37 full-time employees plus 1 employee on leave of absence, zero part-time employees and zero full-time consultants.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?